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Abstract 
Dengue viruses, mosquito-borne members of the Flaviviridae family, are the causative agents 
of dengue fever and its associated complications, dengue haemorrhagic fever and dengue 
shock syndrome. To date, more than 2.5 billion people in over 100 countries are at risk of 
infection, and approximately 20 million infections were reported annually. There is currently 
no treatment or vaccine available for dengue infection. This study employed a whole-cell 
organism model or in vitro methods to study the inhibitory property of the flavanoid-derived 
compounds against DENV2 activity. Results showed that at concentration not exceeding the 
maximum non-toxic dose (MNTD), these compounds completely prevented DENV2 infec-
tion in HepG2 cells as indicated by the absence of cytophatic effects. The in vitro antiviral 
activity assessed in HepG2 cells employing virus inhibition assay showed high inhibitory ac-
tivity in a dose dependent manner. At concentration below MNTD, compounds exhibited 
inhibitory activity against DENV2 with a range of potency strengths of 72% to 100%. The 
plaque forming unit per ml (pfu/ml) was reduced prominently with a maximum reduction of 
98% when the infected HepG2 cells were treated with the highest non-toxic dose of com-
pounds. The highly potent activity of the compounds against DENV2 infection strongly sug-
gests their potential as a lead antiviral agent for dengue.  
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INTRODUCTION 
Dengue is recently reported to be the most ra-
pidly spreading mosquito-borne viral disease (1, 2) 
and is endemic in more than 110 countries with 
two-fifths of the world population at risk. An esti-
mated 100 million cases of dengue fever and half a 
million cases of dengue haemorrhagic fever (DHF) 
occurred annually (3). The disease is caused by den-
gue virus which exists as four closely related, but an-
tigenically distinct virus serotypes of DENV1 to 4 (4). 
This leads to many challenges in the development of a 
vaccine that would provide solid immunity equally to 
all serotypes (5). Another approach of viral diseases 
control is directed toward antiviral activities. Re-
search for dengue antiviral has focused on the differ-
ent phases of the viral lifecycle (virus attachment, 
viral entry, trafficking, translation or replication). 
Nevertheless, only few antiviral therapies have been 
tested and little is known about the effects and me-
chanisms of the antiviral agents (6). 
This study aims to evaluate the in vitro inhibitory 
potential of a group of compound synthesized based 
on flavanoids of natural product template toward 
DENV2 infection using human cell culture model.  
Materials and Methods 
Cell culture 
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Virus stocks 
 The dengue virus type-2 (DENV2) strain used in 
this study is a prototype of New Guinea C strain ob-
tained from the Medical Microbiology Department in 
the Faculty of Medicine, University of Malaya. The 
virus stock was prepared by inoculating monolayer of 
C6/36 cells in a 25-cm2 tissue culture flask with virus 
diluted 1:5 to 1:10 in 1 mL of Leibovitz’s L-15 con-
taining 2% FBS. The flask was placed in an incubator 
at 28°C to allow virus adsorption. After 1 hour, 4 mL 
of Leibovitz’s L-15 supplemented with 2% FBS was 
added and the cells were allowed to continue propa-
gating at 28°C for 6 to 7 days until the cytophatic ef-
fect (CPE) are confirmed. The cells and supernatant 
were then harvested by gentle pipetting. Cell debris 
was removed by centrifugation at 1,500 x g for 5 mi-
nutes. The viral supernatant was collected in aliquots 
of 1 mL each and stored at -80°C until further use. 
Virus titration by plaque assay 
  DENV2 virulence was titrated by plaque assay 
using BHK21 cells as previously described (8). Briefly, 
BHK21 cell was seeded in 6-well plates (6 x 105 
cells/well) in DMEM with 10% FBS for 24 hours at 
37°C. After cell propagation, growth medium was 
removed and serial dilutions of viral supernatants in 
DMEM with 2% FBS were added to the wells. The 
inoculated cells were further incubated to allow virus 
adsorption for 2 hours at 37°C. Subsequently, a mix-
ture of agar overlay was added and the plates were 
incubated at 37°C for 5 days or until formation of 
plaque. The plaques were visualized after removal of 
the agar plug and staining with 0.1% naphthalene 
black solution in 6% acetic acid glacial. The virus titre 
is expressed as plaque forming unit (PFU) per millili-
tre.  
Cytotoxicity screening of synthesized com-
pounds 
The in vitro cytotoxicity analysis was carried out 
on the synthesized compounds to determine the 
maximum non-toxic dose (MNTD) to HepG2 cells. 
Since these compounds were dissolved in methanol 
for testing, the cytotoxicity analysis is initiated with a 
control experiment using only methanol. The concen-
trated stock of compounds were mixed with DMEM 
of 2% FBS and made to different concentrations before 
added to preformed monolayer of HepG2 cells in 
96-well plates. A series of suitable control for in vitro 
MNTD determination was included in every plate 
and the plates were incubated in the optimum envi-
ronment for HepG2 cells. The MNTD of test com-
pounds was analysed with a colorimetric assay using 
tetrazolium salt MTT at end-point of 96 hours 
post-incubation.  
The in vitro inhibition assay 
The  in vitro inhibition assay of synthesized 
compounds was carried out in three sets of experi-
ments with four replicates for each reaction. For each 
experiment, a 10-fold dilutions corresponding to 1000 
– 10 TCID50 of DENV2 virus stock was prepared in 
DMEM with 2% FBS. Subsequently, preformed mo-
nolayer of HepG2 cells in either a 24-well plate (1 X 
105 cells/well) or a 96-well plate (1 X 104 cells/well) 
was inoculated with serially diluted DENV2 for 1 
hour at 37°C with presence of CO2 at 5%. The reaction 
set up included control wells for the cells, virus and 
compound. Meanwhile, the concentrated stocks of the 
synthesized compounds were diluted with DMEM 
(2% FBS) to different concentrations within their re-
spective maximum non-toxic doses range. At 1 hour 
post-infection, the cells were treated accordingly and 
incubated in the same environment.  
The 24-well plate test groups were observed by 
phase contrast microscope on a daily basis for 4 days 
to detect any prevention of cytophatic effect (CPE) by 
the compounds. At post- 48 hours and 96 hours in-
cubation time, the 96-well plate test groups were 
measured for the potency of inhibition using CellTiter 
96® AQueous One Solution Cell Proliferation assay 
(Promega Corp.). At post- 48 hours and 96 hours in-
cubation time, culture medium was collected from 
another 24-well test plate, aliquoted into several 1.5 
mL Eppendorf tubes, labelled and kept at -80
°C for 
virus plaque assay.  
Statistical analysis 
Statistical analysis on the potency of inhibition 
was done using the Kruskal-Wallis test of SPSS ver-
sion 17.0 software. It is a non-parametric test between 
groups analysis of variance which allows comparison 
of scores on continuous variable for three or more 
groups. The significance level, p less than 0.05 
(p<0.05) or p less than 0.001 (p<0.001) will indicate 
significant difference in the continuous variable 
across the test groups.  
RESULTS 
Maximum non-toxic dose (MNTD) of synthe-
sized compounds 
 The maximum non-toxic dos e  o f  m e t h a n o l  i n  
HepG2 cells was determined prior to the cytotoxicity 
analysis. The MNTD for methanol was 6% (v/v) 
(Figure 1a). Thus, subsequently all compounds were 
prepared in methanol at concentrations lower than 
the methanol toxic dose. The relative toxicity plot 
against different concentrations of the five synthe-Int. J. Biol. Sci.
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Figure 4: Virus plaque assay following in vitro inhibition activity of synthesized compounds. All plaques were photographed 
and counted at day 5 of incubation. [ ] denotes concentration of compound in μg/ml; plaques are expressed as plaque 
forming unit per ml (pfu/ml) 
 
 
 DISCUSSION 
Inhibition of DENV2 protease activities by two 
classes of natural products, the flavanones and chal-
cone extracted from an Asian fingerroot Boesenbergia 
rotunda has been reported in an earlier study (9). The 
bioactive natural products from the study are used as 
a template to design and synthesis new compounds 
that could possess inhibitory property toward dengue 
virus infection. The antiviral activity of these synthe-
sized compounds was established in this study em-
ploying the cell culture system which reflects the vi-
rus-host interaction toward any effectors. 
The cell culture system used for in vitro screening 
of the compounds and inhibition assay was the hu-
man hepatoma, HepG2 cells. These cells were chosen 
since cells of the hepatocyte lineage are implicated in 
the  in vivo pathogenesis of DENV infection where 
patients with dengue fever and DHF often showed 
evidence of liver injury (10). Electron micrograph of Int. J. Biol. Sci. 2010, 6 
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HepG2 cells infected by dengue virus showed pres-
ence of intracellular virus particles originating from 
its replication site, the endoplasmic reticulum (11). 
Prior to screening, the pharmacological activity of the 
compound should be distinguished from being toxic 
to the cells. Results on the maximum non-toxic dose 
(MNTD) of these compounds indicated toxicity level 
at the high average value of 27 μg/mL. This suggests 
the compounds to be highly effective even at the 
lowest chemotherapeutic dose hence it is safe to be 
used for animal studies. 
As observed in the results (shown in Figure 2), 
the synthesized compounds exhibited protective ef-
fect against DENV2 infection in HepG2 cells as indi-
cated by the absence of cytophatic effect (CPE). CPE 
induced cells experienced massive morphological 
changes which often include increased in size 
(hyperthrophy) or necrosis presented as clear and 
opaque circles. Observations on HepG2 cells treated 
with non-toxic doses of these compounds at one hour 
post infection by various titres of DENV2 showed no 
characteristic changes in the cell. The normal state of 
HepG2 monolayer consisted of multipolar cells were 
completely preserved and remained intact throughout 
the test period. 
A detailed evaluation on the inhibitory potential 
of all the compounds performed in the in vitro inhibi-
tion assay is adapted from previous studies (12, 13). In 
the in vitro assay, the inhibitory potential is calculated 
relative to the mitochondrial metabolic activity within 
the culture model. This activity is relative to the 
changes in cellular proliferation and viability due to 
infection and treatment of compounds. The cell via-
bility was then measured quantitatively using the 
MTS tetrazolium reagent (CellTiter 96® AQueous One 
Solution Cell Proliferation Assay - Promega). The ab-
sorbance at 490nm is directly proportional to the 
number of living cells in culture, which relatively de-
picted the potency of inhibition by the compounds, 
and converted into percentage of inhibition compara-
tive to the control. The measurement on the viability 
of the cells which indicated any value at or above 70% 
to be prominent and of good significance. Results 
showed that the synthesized compounds to inhibit 
DENV2 infection in a dose-dependent response in 
which all samples presented significantly high level of 
inhibitory activity. However, compound YK51 was 
found to be the most potent whereby in addition of 
being the least toxic with MNTD of 40 μg/ml, at a low 
concentration of 2 μg/mL, it has strong inhibition 
activity of 90% toward the highest virus titre of 1000 
TCID50.  
The inhibitory potential of compounds was also 
evaluated based on the value of DENV2 virus par-
ticles. Virus plaque assay has been considered the 
gold standard for antiviral susceptibility test (14). In 
this study, the technique was employed on culture 
medium retrieved from selected inhibitory assay. 
Results clearly showed that with increased dose of 
inhibitors, the forming of plaque was reduced. Com-
pared with the inoculated monolayer of 4.6 X 103 
pfu/mL, virus plaque count was reduced by ten-fold 
with treatment of the compounds. 
Since all five compounds (YK 38, YK 51, YK 73, 
YK 73x and YK 101) were designed based on the same 
flavanoids as the template, it is expected that these 
compounds possess the same comparable level of 
activity against DENV2 infection. The functional 
group that is proposed to be important for the activity 
is identified as the saturated piperidine ring, which is 
the skeletal structure of all the compounds except in 
the case of YK 38. For YK 38, the unsaturated piperi-
dine ring renders the conformation to be slightly dif-
ferent from the others. Presumably, this resulted in 
YK 38 to possess a different mode of action. Another 
functional group that was observed to be important 
for the activity of the compound is the carbamates or 
BOC (butylated oxycarbamates) group attached to the 
piperidinyl substituents. This functional group is 
present in compounds YK 51, YK 73 and YK 73x but 
not YK 101 where it is replaced by a hydrogen atom. 
Further study is needed to elucidate the mechanism of 
action by these flavanoid-derived compounds with 
relation to their molecular structure.  
The results from this study have shown the in-
hibition of DENV2 in vitro by the synthesized com-
pounds to be significant and hence they could poten-
tially be considered as lead to a ‘new’ class of com-
pounds as antiviral agent for dengue. In addition, 
new challenges arise in determining the mechanism of 
action against dengue by these compounds.  
ACKNOWLEDGEMENTS  
This work was supported by the Top-Down Na-
tional Biotechnology Directory grant of Malaysia 
(09-02-04-001BTK/TH/004 [UM 36-02-03-6008]) and 
Science Fund from the Ministry of Science, Technol-
ogy and Innovation, Malaysia (12-02-03-2005). 
CONFLICT OF INTERESTS  
All synthesized compounds used in this study 
have been submitted for Malaysia patent filing and 
the University of Malaya is the owner of the patent 
(Receipt No. : RST/IP-054844-2009). The university 
holds the rights for all the financial benefits that may 
result from this research. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
302
REFERENCES 
1.   [Internet] WHO. Dengue Guidelines for Diagnosis, Treatment, 
Prevention and Control; New Edition 2009; A joint publication 
of the World Health Organization (WHO) and the Special Pro-
gramme for Research and Training in Tropical Diseases (TDR). 
http://whqlibdoc.who.int/publications/2009/9789241547871_
eng.pdf 
2.  Halstead SB, Heinz FX, Barrett ADT and Roehrig JT. Dengue 
virus: molecular basis of cell entry and pathogenesis, 25-27 June 
2003, Vienna, Austria. Vaccine. 2005; 23: 849-856. 
3.  Malavige GN, Fernando S, Fernando DJ and Seneviratne SL. 
Dengue viral infections. Postgrad Med J. 2004; 80: 588-601. 
4.  Henchal EA and Putnak JR. The dengue viruses. Clin Microbiol 
Rev. 1990; 3(4): 376-396. 
5.  Halstead SB and Deen J. The future of dengue vaccines. Lancet. 
2002; 360: 1243-1245. 
6.  Sampath A and Padmanabhan R. Molecular targets for flavi-
virus drug discovery. Antiviral Research. 2009; 81: 6-15. 
7.  Lee YK. Synthesis for potential inhibitor as therapeutics agent 
against dengue virus protease (PhD Thesis). University of Ma-
laya.  2010. 
8.  Morens DM, Halstead SB, Repik PM, Putvatana R and Ray-
bourne N. Simplified plaque reduction neutralization assay for 
dengue viruses by semimicro methods in BHK-21 cells: com-
parison of the BHK suspension test with standard plaque re-
duction neutralization. J Clin Microbiol. 1985; 22: 250-254.  
9.  Tan SK, Pippen R, Yusof R, Ibrahim H, Khalid N and Rahman 
NA. Inhibitory activity of cyclohexenyl chalcone derivatives 
and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards 
dengue-2 virus NS3 protease. Bioorg Med Chem Lett. 2006; 16: 
3337-3340. 
10.  Phoolcharoen W and Smith DR. Internalization of the dengue 
virus is cell cycle modulated in HepG2, but not Vero cells. J 
Med Virol. 2004; 74(3): 434-441. 
11.  Marianneau P, Steffan AM, Royer C, Drouet MT, Kirn A and 
Deubel V. Differing infection patterns of dengue and yellow fever 
viruses in a human hepatoma cell line. J Infect Dis. 1998; 178: 
1270-1278. 
12.  Premanathan M, Kathiresan K, Yamamoto N and Nakashima 
H. In vitro anti-human immunodeficiency virus activity of po-
lysaccharide from Rhizopora mucronata Poir. Biosci Biotechnol 
Biochem. 1999; 63(7): 1187-1191. 
13.  Parida MM, Upadhyay C, Pandya G and Jana AM. Inhibitory 
potential of neem (Azadirachta indica Juss) leaves on dengue 
virus type-2 replication. J Ethnopharm. 2002; 79: 273-278. 
14.  Wentworth BB and French L. Plaque assay of cytomegalovirus 
strains of human origin. Proc Soc Exp Biol Med. 1970; 135(2): 
253-258. 